



## “Low Dose Radiotherapy for Osteoarthritis, Plantar Fasciitis, and Dupuytren’s”

This activity has been approved for *AMA PRA Category 1 Credit™*



**Dennis L. Carter, MD**  
Board Certified Radiation Oncology



Wednesday, March 12<sup>th</sup>, 2025



12:00pm – 1:00pm MST



HCA HealthONE Aurora’s Physician Conference Room



Join Virtually:

<https://hcaconnect.webex.com/hcaconnect/j.php?MTID=m2daabd10af5a2dd6e8f8f15cbdee7bcb>



**Description:** This presentation will review the rationale and mechanisms of action for the use of low dose radiotherapy as an anti-inflammatory treatment in patients with osteoarthritis, plantar fasciitis, and Dupuytren’s disease. The relevant literature reporting clinical outcomes will be reviewed, including reports of efficacy, side effects, and risks. Appropriate patient selection for low dose radiotherapy will be identified, in the context of the natural history and alternative interventions.

**Audience:** This course is designed for hospitalists, nurse practitioners, physician assistants, advance practice nurses, registered nurses, allied health professionals, physicians and residents.

**At the end of this session, learners will be able to:**

1. Describe the anti-inflammatory rationale and mechanisms of action for low dose radiotherapy for osteoarthritis, plantar fasciitis, and Dupuytren’s disease.
2. Recall relevant clinical medical literature for such treatments.
3. Identify appropriate patient profiles to consider for low dose radiotherapy for osteoarthritis, plantar fasciitis, and Dupuytren’s disease.

**Accreditation:** The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians  
**Credit Designation:** The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 *AMA PRA Category 1™*. Physician should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:** This Activity was developed without support from any ineligible company.

**\*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, an ACCME defined ineligible company.**

**Disclosure:** The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidence-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.

Please reach out to [CME@HCAHealthONE.com](mailto:CME@HCAHealthONE.com) with any questions.